Benjamin F. Edwards & Company, Inc. Aptinyx Inc. Transaction History

Benjamin F. Edwards & Company, Inc.

  • $5.69 Billion
  • Q2 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2019

Feb 06, 2020
SELL
$2.84 - $4.25 $497 - $743
-175 Closed
0 $0
Q4 2018

Jan 31, 2019
SELL
$16.15 - $28.93 $23,417 - $41,948
-1,450 Reduced 89.23%
175 $3,000
Q3 2018

Oct 29, 2018
BUY
$20.21 - $31.85 $32,841 - $51,756
1,625 New
1,625 $47,000

About Aptinyx Inc.

APTX Quotes by TradingView
  • Ticker APTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 67,715,696
  • Description
  • Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic pe...
More about APTX
Track This Portfolio

Track Benjamin F. Edwards & Company, Inc. Portfolio

Follow Benjamin F. Edwards & Company, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Benjamin F. Edwards & Company, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Benjamin F. Edwards & Company, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email